MCID: DST006
MIFTS: 45

Diastolic Heart Failure

Categories: Cardiovascular diseases

Aliases & Classifications for Diastolic Heart Failure

MalaCards integrated aliases for Diastolic Heart Failure:

Name: Diastolic Heart Failure 12 15 17
Heart Failure, Diastolic 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9775
ICD9CM 34 428.3
MeSH 43 D054144
SNOMED-CT 67 418304008
ICD10 32 I50.30
UMLS 71 C1135196

Summaries for Diastolic Heart Failure

MalaCards based summary : Diastolic Heart Failure, also known as heart failure, diastolic, is related to idiopathic edema and constrictive pericarditis. An important gene associated with Diastolic Heart Failure is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are p70S6K Signaling and Pathways in cancer. The drugs Atorvastatin and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Diastolic Heart Failure

Diseases related to Diastolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 250)
# Related Disease Score Top Affiliating Genes
1 idiopathic edema 30.9 NPPB NPPA ACE
2 constrictive pericarditis 30.8 TTN NPPB ACE
3 muscle hypertrophy 30.5 TTN NPPA AGT
4 congestive heart failure 30.5 TTN REN NPPB NPPA NOS3 MYBPC3
5 restrictive cardiomyopathy 30.5 TTN NPPB MYBPC3 ACE
6 coronary heart disease 1 30.5 NPPB NOS3 AGTR1 ACE
7 atrial standstill 1 30.5 TTN NPPB NPPA MYBPC3 ACE
8 hypertension, diastolic 30.4 REN ACE
9 amyloidosis 30.4 TTN NPPB MYBPC3 CST3
10 systolic heart failure 30.4 TTN NPPB NPPA NOS3 MMP9 MMP2
11 rheumatic heart disease 30.3 TGFB1 NPPB ACE
12 pulmonary edema 30.3 REN NPPB NPPA NOS3 AGTR1 AGT
13 mitral valve insufficiency 30.3 REN NPPB NPPA MYBPC3 ACE
14 pulmonary hypertension 30.2 REN NPPB NPPA NOS3 AGTR1 ACE
15 atherosclerosis susceptibility 30.2 NOS3 MMP9 AGTR1 ACE
16 left bundle branch hemiblock 30.2 REN NPPB ACE
17 cardiac tamponade 30.2 REN NPPB ACE
18 sleep apnea 30.1 REN NPPB NOS3 AGT ACE
19 arteriosclerosis 30.1 NOS3 MMP9 CST3 ACE
20 patent ductus arteriosus 1 30.1 REN NPPB ACE
21 eclampsia 30.0 REN NOS3 AGT ACE
22 heart valve disease 29.9 TGFB1 REN NPPB NPPA MIR499A ACE
23 central sleep apnea 29.8 REN NPPB NPPA NOS3 ACE
24 end stage renal disease 29.8 REN NOS3 CST3 AGTR1 AGT ACE
25 arteries, anomalies of 29.8 REN NOS3 MIR499A AGTR1 ACE
26 respiratory failure 29.7 TTN REN NPPB NPPA ACE
27 polycystic kidney disease 29.5 REN NOS3 CST3 AGTR1 AGT ACE
28 lipoprotein quantitative trait locus 29.5 REN NPPB NPPA NOS3 MMP9 AGTR1
29 cardiac arrest 29.5 TTN REN NPPB MYBPC3 ACE
30 hypertensive heart disease 29.4 REN NPPB NPPA MMP9 MMP2 MMP1
31 renal hypertension 29.3 REN NPPB NOS3 CYBB AGTR1 AGT
32 autosomal dominant polycystic kidney disease 29.2 TGFB1 REN NOS3 CST3 AGTR1 AGT
33 kidney disease 29.1 TGFB1 REN NPPB NPPA NOS3 CST3
34 aortic valve disease 2 29.1 TTN REN NPPB NPPA MYBPC3 AGT
35 mitral valve disease 29.0 REN NPPB NPPA NOS3 MMP1 AGTR1
36 stroke, ischemic 28.8 REN NPPB NPPA NOS3 MMP9 CST3
37 pre-eclampsia 28.7 REN NPPA NOS3 MMP9 MMP2 CST3
38 cardiovascular system disease 28.7 REN NPPB NPPA NOS3 MIR499A CST3
39 heart disease 28.7 TTN TGFB1 REN NPPB NPPA NOS3
40 chronic kidney disease 28.7 TGFB1 REN NPPB NPPA NOS3 MMP9
41 vascular disease 28.6 TGFB1 REN NPPB NOS3 MMP9 CYBB
42 atrial fibrillation 28.5 TTN TGFB1 REN NPPB NPPA NOS3
43 diabetes mellitus 28.4 TGFB1 REN NPPB NOS3 MMP9 MMP2
44 hypertrophic cardiomyopathy 28.3 TTN TGFB1 REN NPPB NPPA NOS3
45 dilated cardiomyopathy 27.0 TTN TGFB1 REN NPPB NPPA NOS3
46 cardiac tuberculosis 10.6 NPPB ACE
47 vasculogenic impotence 10.6 NPPA ACE
48 toxic myocarditis 10.5 NPPB ACE
49 progressive muscular dystrophy 10.5 NPPA CCN2
50 anterolateral myocardial infarction 10.5 NPPB NPPA ACE

Graphical network of the top 20 diseases related to Diastolic Heart Failure:



Diseases related to Diastolic Heart Failure

Symptoms & Phenotypes for Diastolic Heart Failure

MGI Mouse Phenotypes related to Diastolic Heart Failure:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 ACE AGT AGTR1 ANKRD1 CCN2 CST3
2 homeostasis/metabolism MP:0005376 10.3 ACE AGT AGTR1 ANKRD1 CCN2 CST3
3 behavior/neurological MP:0005386 10.23 ACE AGT AGTR1 ANKRD1 CYBB MADD
4 growth/size/body region MP:0005378 10.18 ACE AGT AGTR1 ANKRD1 CCN2 CYBB
5 mortality/aging MP:0010768 10.07 ACE AGT AGTR1 CCN2 CST3 CYBB
6 immune system MP:0005387 10.06 ACE AGT AGTR1 CYBB MMP1 MMP2
7 muscle MP:0005369 9.93 AGT ANKRD1 CST3 CYBB MMP2 MMP9
8 neoplasm MP:0002006 9.5 ACE CST3 CYBB MMP1 MMP2 MMP9
9 renal/urinary system MP:0005367 9.28 ACE AGT AGTR1 CYBB MMP9 NOS3

Drugs & Therapeutics for Diastolic Heart Failure

Drugs for Diastolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4 134523-00-5 60823
2
Adalimumab Approved Phase 4 331731-18-1 16219006
3
Infliximab Approved Phase 4 170277-31-3
4
Etanercept Approved, Investigational Phase 4 185243-69-0
5
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
6
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Allopurinol Approved Phase 4 315-30-0 2094
10
Adenosine Approved, Investigational Phase 4 58-61-7 60961
11
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
12
Amlodipine Approved Phase 4 88150-42-9 2162
13
Empagliflozin Approved Phase 4 864070-44-0
14
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
15
Eplerenone Approved Phase 4 107724-20-9 150310 443872
16
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
17
Glucagon Approved Phase 4 16941-32-5
18
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
19
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
20
Uric acid Investigational Phase 4 69-93-2 1175
21 Hypolipidemic Agents Phase 4
22 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
23 Lipid Regulating Agents Phase 4
24 Anticholesteremic Agents Phase 4
25 Analgesics, Non-Narcotic Phase 4
26 Analgesics Phase 4
27 Anti-Inflammatory Agents Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Gastrointestinal Agents Phase 4
30 Immunosuppressive Agents Phase 4
31 Dermatologic Agents Phase 4
32 Hormones Phase 4
33 Calcium, Dietary Phase 4
34 calcium channel blockers Phase 4
35 Angiotensin II Type 1 Receptor Blockers Phase 4
36 Angiotensinogen Phase 4
37 Angiotensin Receptor Antagonists Phase 4
38 Giapreza Phase 4
39 Antimetabolites Phase 4
40 Dopamine Agents Phase 4
41 Sympathomimetics Phase 4
42 Hypoglycemic Agents Phase 4
43 Phosphodiesterase Inhibitors Phase 4
44 Phosphodiesterase 5 Inhibitors Phase 4
45 Citrate Phase 4
46 Sildenafil Citrate Phase 4 171599-83-0
47 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
48 LCZ 696 Phase 4
49 Vasodilator Agents Phase 4
50 Neurotransmitter Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 169)
# Name Status NCT ID Phase Drugs
1 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
2 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
3 A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure Completed NCT00171106 Phase 4 valsartan
4 Novel Treatment for Diastolic Heart Failure in Women Completed NCT00206232 Phase 4 Spironolactone
5 Randomized Evaluation of Heart Failure With Preserved Ejection Fraction (HFpEF) Patients With Acute Heart Failure and Dopamine (ROPA-DOP) Trial Completed NCT01901809 Phase 4 Furosemide;Dopamine
6 Aldosterone Antagonism in Diastolic Heart Failure Completed NCT00108251 Phase 4 Eplerenone;Placebo
7 Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart Completed NCT01944384 Phase 4 aldactone
8 SIDAMI - Sildenafil and Diastolic Dysfunction After AMI Completed NCT01046838 Phase 4 Sildenafil;Placebo
9 Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients Completed NCT00477789 Phase 4 allopurinol
10 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Completed NCT02589977 Phase 4 regadenoson
11 Fimasartan for Improvement of Diastolic Dysfunction in Hypertensive Patients Completed NCT01691118 Phase 4 Fimasartan;Antihypertensive treatment
12 Effect of Add-on of Amlodipine Versus Valsartan on Diastolic Dysfunction Associated With Hypertension Completed NCT02973035 Phase 4 Amlodipine;Valsartan
13 DAPA-LVH - Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? Completed NCT02956811 Phase 4 Dapagliflozin;Placebo
14 A Phase 4, Single-center, Randomized, Parallel Group Study to Assess Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus Recruiting NCT03753087 Phase 4 Empagliflozin
15 A Proof of Concept Study to Determine the Efficacy of Entresto™ in HFpEF Based on Circulating Neprilysin Levels: The Circulating NEP and NEP Inhibition (CNEPi) Study Recruiting NCT03506412 Phase 4 Entresto™ 49Mg-51 mg tablet
16 Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure Active, not recruiting NCT02053246 Phase 4 Nebivolol
17 A Phase 4, Randomized, Open Label, Multicenter Prospective Comparative Study To Evaluate The Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure Not yet recruiting NCT04160000 Phase 4 Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation
18 The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure Not yet recruiting NCT04071626 Phase 4 Ertugliflozin 5 mg;Placebo oral tablet
19 Determine the Effectiveness of Eplerenone in Reversing Diastolic Dysfunction, Improving Endothelial Function, and Suppressing Natriuretic Peptides and Collagen Turnover in Patients With Diastolic Heart Failure ( PREDICT Study) Terminated NCT00293150 Phase 4 Eplerenone
20 Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction Terminated NCT00799435 Phase 4 Exenatide
21 The Use of Nesiritide in the Management of Acute Diastolic Heart Failure Terminated NCT00083772 Phase 4 Nesiritide
22 Safety and Efficacy Trial Using Ambrisentan for Pulmonary Hypertension Associated With Congestive Heart Failure With Preserved Left Ventricular Ejection Fraction Terminated NCT00840463 Phase 4 Ambrisentan
23 Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction Unknown status NCT01583881 Phase 2, Phase 3
24 Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction: Phase III, Randomized, Double-blind, Placebo-controlled Trial [ULTIMATE-HFpEF Trial] Unknown status NCT01599117 Phase 3 Placebo;Udenafil (Zydena)
25 Exercise Intolerance in Elderly Diastolic Heart Failure Completed NCT00123955 Phase 3 Spironolactone;Placebo
26 Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure Completed NCT01411735 Phase 3 Enalapril;placebo
27 Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Completed NCT00763867 Phase 3 Placebo;Sildenafil
28 Effects of Sildenafil on Pulmonary Arterial Pressure in Patients With Heart Failure With Preserved Ejection Fraction ( HFpEF) and Pulmonary Hypertension Completed NCT01726049 Phase 3 Sildenafil;Placebo
29 Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study Completed NCT01156636 Phase 2, Phase 3 Sildenafil;Placebo
30 Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Completed NCT00094302 Phase 3 Spironolactone;Placebo
31 A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction Completed NCT01920711 Phase 3 LCZ696;Valsartan
32 Aldosterone-blockade Randomized Controlled Trial In CHF - Diastolic Completed NCT00523757 Phase 3 Spironolactone;Placebo
33 Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension Completed NCT00820352 Phase 3 bosentan;placebo
34 Candesartan "Added" Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months Completed NCT00775840 Phase 3 Candesartan;Placebo
35 MB001-067 A PROSPECTIVE, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, RANDOMIZED TRIAL OF EXTENDED RELEASE EXENATIDE VERSUS PLACEBO (COHORT A) AND A PROSPECTIVE, SINGLE GROUP, OPEN-LABEL, BLINDED OUTCOME TRIAL OF EXTENDED RELEASE EXENATIDE (COHORT B) IN DIABETIC PATIENTS WITH TYPE 4 CARDIORENAL SYNDROME (EXTEND-CRS TRIAL) AMENDMENT 3 Recruiting NCT02251431 Phase 3 BYDUREON;Placebo
36 Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) (OPTIMIZE-HFPEF) Recruiting NCT02425371 Phase 3
37 A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer Terminated NCT01708798 Phase 2, Phase 3 Eplerenone;Placebo
38 A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study Completed NCT00043836 Phase 2 ALT-711
39 A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure. Completed NCT00309868 Phase 1, Phase 2 neseritide
40 A Phase 2 Randomised, Double-Blind, Placebo-Controlled Exploratory Efficacy Study Of Sitaxsentan Sodium To Improve Impaired Exercise Tolerance In Subjects With Diastolic Heart Failure Completed NCT00303498 Phase 2 Sitaxsentan sodium;Placebo
41 Evaluation of Efficacy and Safety of Metoprolol XR in Patients Having Heart Failure With Normal Ejection Fraction: A Randomised, Double Blind,Placebo Controlled Trial Completed NCT03882710 Phase 2 Metoprolol XR
42 A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction Completed NCT01163734 Phase 2 Ranolazine
43 Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF) Completed NCT00839228 Phase 2 Perhexiline;Placebo
44 To Define in Normal Controls, Human Preclinical Systolic Dysfunction (PSD) and Preclinical Diastolic Dysfunction (PDD) the Actions of Acute Subcutaneous Nesiritide (BNP) on the Cardiorenal and Humoral Function and the Integrated Response to Acute Sodium Loading Completed NCT00387621 Phase 1, Phase 2 Nesiritide;Placebo;Saline
45 Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function Completed NCT01182805 Phase 1, Phase 2
46 Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF Completed NCT02256345 Phase 2 KNO3;KCl
47 A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension Completed NCT01431313 Phase 2 Inhaled Nitrite
48 Interleukin-1 Blockade in Heart Failure With Preserved Ejection Fraction (HFpEF): a Randomized Placebo-controlled Double Blinded Study (D-HART2) Completed NCT02173548 Phase 2 Anakinra;Placebo
49 Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose Recruiting NCT03133793 Phase 2 CoQ10;D-Ribose Oral Powder
50 Regress-HFPEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs Recruiting NCT02941705 Phase 2

Search NIH Clinical Center for Diastolic Heart Failure

Cochrane evidence based reviews: heart failure, diastolic

Genetic Tests for Diastolic Heart Failure

Anatomical Context for Diastolic Heart Failure

MalaCards organs/tissues related to Diastolic Heart Failure:

40
Heart, Brain, Testes, Kidney, Endothelial, Lung, Breast

Publications for Diastolic Heart Failure

Articles related to Diastolic Heart Failure:

(show top 50) (show all 1237)
# Title Authors PMID Year
1
Exercise and fluid challenge during right heart catheterisation for evaluation of dyspnoea. 61
32577217 2020
2
Development of a Risk Score for Atrial Fibrillation in Adults With Diabetes Mellitus (from the ACCORD Study). 61
32291091 2020
3
Associations of adiponectin and leptin with brain natriuretic peptide in African Americans: the Jackson Heart Study. 61
32537565 2020
4
Assessment of left-ventricular diastolic function in pediatric intensive-care patients: a review of parameters and indications compared with those for adults. 61
32506345 2020
5
Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study. 61
32277607 2020
6
Clinical, Demographic, and Imaging Correlates of Anemia in Heart Failure With Preserved Ejection Fraction (from the RELAX Trial). 61
32307089 2020
7
The Unraveling: Cardiac and Musculoskeletal Defects and Their Role in Common Alzheimer Disease Morbidity and Mortality. 61
32407731 2020
8
Constrictive Pericarditis: A Commonly Missed Cause of Treatable Diastolic Heart Failure. 61
32528763 2020
9
Comprehensive review of pericardial diseases using different imaging modalities. 61
32048125 2020
10
The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. 61
32472523 2020
11
The Heart Failure with Preserved Ejection Fraction Conundrum-Redefining the Problem and Finding Common Ground? 61
32112345 2020
12
Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure. 61
31822569 2020
13
HAND1 loss-of-function within the embryonic myocardium reveals survivable congenital cardiac defects and adult heart failure. 61
31286141 2020
14
Alterations on a key nephrogenic/cardiogenic gene expression linked to hypertension development. 61
31472952 2020
15
Gut microbiome of a porcine model of metabolic syndrome and HF-pEF. 61
32031871 2020
16
Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). 61
32063068 2020
17
Acute Hemothorax Causing Hemorrhagic Shock Following Small-bore Thoracocentesis in a Patient on Clopidogrel: A Case Report and Literature Review. 61
32351811 2020
18
BRASH syndrome. 61
32094236 2020
19
Constrictive pericarditis masquerading as hepatic sequestration crisis in a patient with sickle cell disease: a case report. 61
32128482 2020
20
Diagnostic and prognostic value of autoantibodies against β1-adrenoreceptors in patients with heart failure following acute myocardial infarction: A 5-year prospective study. 61
32010297 2020
21
Use of a Virtual Mock Loop model to evaluate a new left ventricular assist device for transapical insertion. 61
32089074 2020
22
Diastolic Heart Failure in Patients With the Fontan Circulation: A Review. 61
32022823 2020
23
The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis. 61
31825134 2020
24
Diastolic Heart Failure: A Review of Current and Future Treatment Options. 61
32101908 2020
25
Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity. 61
32019991 2020
26
Risk assessment of post-discharge mortality among recently hospitalized Medicare heart failure patients with reduced or preserved ejection fraction. 61
31469001 2020
27
Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis. 61
32030562 2020
28
Left atrial assist device to treat patients with heart failure with preserved ejection fraction: Initial in vitro study. 61
32089348 2020
29
Left Ventricular Diastolic Dysfunction and Diastolic Heart Failure in Preterm Infants. 61
31598743 2019
30
Thyroid and Heart: Severe Three Vessel Coronary Artery Disease in a Middle-Aged Female with Hypothyroidism. 61
31857927 2019
31
[Clinical classification and characteristics of alcoholic myocardial injury]. 61
31694119 2019
32
HOSPITAL Score, LACE Index and LACE+ Index as predictors of 30-day readmission in patients with heart failure. 61
31771947 2019
33
The prevalence and predictors of resistant hypertension in high-risk overweight and obese patients: A cross-sectional study based on the 2017 ACC/AHA guidelines. 61
31448866 2019
34
Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation. 61
31754623 2019
35
Is echocardiography mandatory for patients with chronic kidney disease? 61
30912000 2019
36
[Heart failure with preserved left ventricular ejection fraction]. 61
31432196 2019
37
Differentiating Constriction from Restriction (from the Mayo Clinic Echocardiographic Criteria). 61
31353007 2019
38
Echocardiographic Diastolic Stress Testing: What Does It Add? 61
31377869 2019
39
Motivational interviewing can support physical activity in elderly patients with diastolic heart failure: results from a pilot study. 61
30963721 2019
40
HIV Infection Is Associated with Greater Left Ventricular Mass in the Multicenter AIDS Cohort Study. 61
31044604 2019
41
[Myocardial Strain Properties in Patients with Chronic Heart Failure]. 61
31397234 2019
42
Identifying a low-flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial. 61
30993916 2019
43
An Approximation of Heart Failure Using Cardiovascular Simulation Toolbox. 61
31295796 2019
44
Emotional intelligence and systolic blood pressure are determinants of cognitive deficits in patients with heart failure. 61
31983738 2019
45
The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure. 61
31140540 2019
46
Morbidity and mortality in patients with cardiovascular risk factors and obstructive sleep apnoea: results from the DIAST-CHF cohort. 61
31252205 2019
47
Accuracy of Administrative Coding to Identify Reduced and Preserved Left Ventricular Ejection Fraction. 61
30743043 2019
48
Adeno-associated virus 9-mediated RNA interference targeting SOCS3 alleviates diastolic heart failure in rats. 61
30763670 2019
49
[Heart failure with preserved ejection fraction (diastolic heart failure)]. 61
31079412 2019
50
[Aortic Intramural Hematoma: a Challenging Diagnosis]. 61
30925605 2019

Variations for Diastolic Heart Failure

Expression for Diastolic Heart Failure

Search GEO for disease gene expression data for Diastolic Heart Failure.

Pathways for Diastolic Heart Failure

Pathways related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.96 TGFB1 REN CCN2 AGTR1 AGT ACE
2 12.73 TGFB1 MMP9 MMP2 MMP1 AGTR1 AGT
3
Show member pathways
12.58 TGFB1 NOS3 MMP9 MMP2 MMP1
4
Show member pathways
12.45 NPPB NPPA NOS3 AGTR1 AGT
5
Show member pathways
12.4 NPPB NPPA NOS3 AGTR1 AGT
6
Show member pathways
12.1 TTN TGFB1 MYBPC3 AGT ACE
7 12.09 TGFB1 MMP9 MMP2 MMP1
8
Show member pathways
12.06 TGFB1 NPPB NPPA AGT
9 11.85 TGFB1 MMP9 MMP2 MMP1
10
Show member pathways
11.79 MMP9 MMP2 MMP1
11 11.67 TGFB1 REN NOS3 MMP9 MMP2
12 11.66 MMP9 MMP2 MMP1
13 11.61 NOS3 MMP9 MMP2
14
Show member pathways
11.57 MMP9 MMP2 MMP1
15 11.55 MMP9 MMP2 MMP1
16 11.5 TGFB1 MMP9 MMP2 CCN2
17 11.43 TGFB1 NOS3 MMP2 CYBB AGTR1 AGT
18 11.42 MMP9 MMP2 CCN2
19 11.39 REN NPPA AGTR1 AGT ACE
20 11.2 NOS3 MMP9 MMP2 MMP1
21 11.19 MMP9 MMP2 ACE
22 11.07 NOS3 MMP9 MMP2
23
Show member pathways
11 TGFB1 REN NOS3 AGTR1 AGT ACE
24 10.92 MMP9 MMP2 CST3 ACE
25 10.86 TGFB1 MMP9 MMP1

GO Terms for Diastolic Heart Failure

Cellular components related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.85 TGFB1 REN NPPB NPPA MMP9 MMP2
2 extracellular matrix GO:0031012 9.65 TGFB1 MMP9 MMP2 MMP1 CCN2
3 sarcomere GO:0030017 9.5 TTN MYBPC3 MMP2
4 collagen-containing extracellular matrix GO:0062023 9.43 TGFB1 NPPA MMP9 MMP2 CCN2 AGT
5 extracellular region GO:0005576 9.4 TTN TGFB1 REN NPPB NPPA MMP9

Biological processes related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.95 NPPA MMP2 MMP1 CST3
2 response to hypoxia GO:0001666 9.92 TGFB1 NPPA MMP2 CST3
3 female pregnancy GO:0007565 9.85 TGFB1 NPPA AGT
4 negative regulation of cell growth GO:0030308 9.85 TGFB1 NPPB NPPA AGT
5 kidney development GO:0001822 9.83 REN AGTR1 AGT ACE
6 extracellular matrix disassembly GO:0022617 9.81 MMP9 MMP2 MMP1
7 response to estradiol GO:0032355 9.81 TGFB1 CST3 CCN2 AGT
8 positive regulation of blood vessel endothelial cell migration GO:0043536 9.79 TGFB1 NOS3 MIR499A
9 positive regulation of protein secretion GO:0050714 9.77 TTN TGFB1 ANKRD1
10 embryo implantation GO:0007566 9.77 MMP9 MMP2 CST3
11 collagen catabolic process GO:0030574 9.76 MMP9 MMP2 MMP1
12 blood vessel remodeling GO:0001974 9.71 NOS3 AGT ACE
13 cellular response to mechanical stimulus GO:0071260 9.71 TGFB1 NPPA ANKRD1 AGT
14 response to amyloid-beta GO:1904645 9.69 MMP9 MMP2
15 cardiac muscle tissue morphogenesis GO:0055008 9.69 TTN ANKRD1
16 amyloid-beta metabolic process GO:0050435 9.68 REN ACE
17 positive regulation of renal sodium excretion GO:0035815 9.68 NPPB AGT
18 low-density lipoprotein particle remodeling GO:0034374 9.68 AGTR1 AGT
19 negative regulation of systemic arterial blood pressure GO:0003085 9.68 NPPB NPPA
20 positive regulation of cardiac muscle cell differentiation GO:2000727 9.67 TGFB1 MIR499A
21 cell activation GO:0001775 9.67 TGFB1 CST3
22 angiotensin maturation GO:0002003 9.66 REN ACE
23 positive regulation of cardiac muscle contraction GO:0060452 9.66 NPPA CCN2
24 cGMP biosynthetic process GO:0006182 9.65 NPPB NPPA
25 receptor guanylyl cyclase signaling pathway GO:0007168 9.65 NPPB NPPA
26 negative regulation of biomineral tissue development GO:0070168 9.64 TGFB1 NOS3
27 positive regulation of cholesterol esterification GO:0010873 9.64 AGTR1 AGT
28 positive regulation of NAD(P)H oxidase activity GO:0033864 9.63 AGTR1 AGT
29 regulation of vasoconstriction GO:0019229 9.63 AGTR1 AGT ACE
30 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.62 MMP9 MMP2 MIR499A AGT
31 connective tissue development GO:0061448 9.61 TGFB1 CCN2
32 negative regulation of extracellular matrix disassembly GO:0010716 9.61 TGFB1 CST3
33 vasodilation GO:0042311 9.61 NPPA NOS3 AGT
34 regulation of renal sodium excretion GO:0035813 9.58 AGTR1 AGT
35 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.57 AGTR1 AGT
36 regulation of blood volume by renin-angiotensin GO:0002016 9.56 REN AGT
37 positive regulation of cellular protein metabolic process GO:0032270 9.54 TGFB1 AGTR1 AGT
38 mononuclear cell proliferation GO:0032943 9.49 TGFB1 ACE
39 regulation of renal output by angiotensin GO:0002019 9.48 AGT ACE
40 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.43 AGTR1 AGT ACE
41 renin-angiotensin regulation of aldosterone production GO:0002018 9.33 REN AGTR1 AGT
42 regulation of blood vessel diameter GO:0097746 9.26 NPPB NOS3 AGTR1 ACE
43 regulation of blood pressure GO:0008217 9.1 REN NPPB NPPA NOS3 AGT ACE

Molecular functions related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.72 REN MMP9 MMP2 MMP1 ACE
2 metallopeptidase activity GO:0008237 9.46 MMP9 MMP2 MMP1 ACE
3 titin binding GO:0031432 9.37 MYBPC3 ANKRD1
4 hormone receptor binding GO:0051427 9.26 NPPB NPPA
5 endopeptidase activity GO:0004175 9.02 REN MMP9 MMP2 MMP1 ACE
6 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE

Sources for Diastolic Heart Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....